Carnitine Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Carnitine, also known as beta-hydroxy-gamma-trimethylammonium butyrate, is a vital water-soluble compound derived from amino acids. Individuals who consume a non-vegetarian diet get the majority of their carnitine from dietary sources, accounting for nearly three-quarters of their total carnitine stores. The primary dietary suppliers of carnitine are red meat, poultry, and dairy products. Carnitine plays a significant role in lipid metabolism and various metabolic pathways. Carnitine deficiency can be either primary, stemming from a defect in carnitine transport, or secondary, caused by other conditions. Primary carnitine deficiency (PCD) is an autosomal recessive genetic disorder resulting from a defect in the OCTN2 (organic carnitine transporter novel type 2) carnitine-transporter system, which is encoded by the SLC22A5 gene. Secondary carnitine deficiency (SCD) can arise from several factors, such as reduced carnitine intake or, more commonly, increased renal excretion as acylcarnitine. SCD can be attributed to various factors, including severe malnutrition, ketogenic diets, significant malabsorption issues, extremely premature infants, and extended parenteral nutrition without sufficient L-carnitine supplementation. Conditions featuring renal tubular dysfunction, like Fanconi syndrome, can exacerbate carnitine losses through the kidneys. Certain medications, such as valproic acid, cyclosporine, pivampicillin, and some anticancer drugs, like etoposide and vinblastine, can contribute to carnitine deficiency. The primary treatment for primary carnitine deficiency involves lifelong administration of high doses of oral L-carnitine, typically ranging from 100 to 200 mg/kg per day, divided into three doses. The oral bioavailability of L-carnitine ranges from 5% to 18%.
Thelansis’s “Carnitine Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Carnitine Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Carnitine Deficiency across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Carnitine Deficiency Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment